Pulmonary Disorders II
Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus
three-times daily regimens of tobramycin treatment
for pulmonary exacerbations of cystic fibrosisβthe
2005;365(9459):573-578.
https://doi.org/10.1016/
s0140-6736(05)17906-9
Smyth AR, Bhatt J, Nevitt SJ. Once-daily versus
multiple-daily dosing with intravenous aminoglyco-
sides for cystic fibrosis. Cochrane Database Syst Rev.
2017;3(3):CD002009. https://doi.org/10.1002/14651858.
cd002009.pub6
Turcios NL. Cystic fibrosis lung disease: an overview.
Respir Care. 2020;65(2):233-251. https://doi.org/10.4187/
respcare.06697
Waters V, Shaw M, Perrem L, et al. A randomised trial
of oral prednisone for cystic fibrosis pulmonary exac-
erbation treatment. Eur Respir J. 2024;63(6):2302278.
https://doi.org/10.1183/13993003.02278-2023
West NE, Beckett VV, Jain R, et al. Standardized
Treatment
of
Pulmonary
Exacerbations
(STOP)
study: physician treatment practices and outcomes for
individuals with cystic fibrosis with pulmonary exacer-
bations. J Cyst Fibros. 2017;16(5):600-606. https://doi.
org/10.1016/j.jcf.2017.04.003
Yankaskas JR, Marshall BC, Sufian B, Simon RH,
Rodman D. Cystic fibrosis adult care: consensus confer-
ence report. Chest. 2004;125(1 suppl):1S-39S. https://doi.
org/10.1378/chest.125.1_suppl.1s
Pulmonary Artery Hypertension
Ammar MA, Sasidhar M, Lam SW. Inhaled epopros-
tenol through noninvasive routes of ventilator support
https://doi.org/10.1177/1060028018782209
Barst RJ, Rubin LJ, Long WA, et al. A comparison of
continuous intravenous epoprostenol (prostacyclin) with
conventional therapy for primary pulmonary hyperten-
sion. N Engl J Med. 1996;334(5):296-301. https://doi.
org/10.1056/nejm199602013340504
Bauer SR, Tonelli AR. Beyond the evidence: treat-
ing pulmonary hypertension in the intensive care unit.
Crit
Care.
2014;18(5):524.
https://doi.org/10.1186/
s13054-014-0524-y
Cascino TM, Sahay S, Moles VM, McLaughlin VV.
A new day has come: sotatercept for the treatment
of pulmonary arterial hypertension. J Heart Lung
Transplant. 2025;44(1):1-10. https://doi.org/10.1016/j.
healun.2024.09.021
Chin KM, Gaine SP, Gerges C, et al. Treatment
algorithm
for
pulmonary
arterial
hypertension.
Eur
Respir
J.
2024;64(4):2401325.
https://doi.
org/10.1183/13993003.01325-2024
Chin KM, Sitbon O, Doelberg M, et al. Three- versus
two-drug therapy for patients with newly diagnosed
pulmonary arterial hypertension. J Am Coll Cardiol.
2021;78(14):1393-1403.
https://doi.org/10.1016/j.
jacc.2021.07.057
Coz Yataco A, Aguinaga Meza M, Buch KP, Disselkamp
MA. Hospital and intensive care unit management of
decompensated pulmonary hypertension and right ven-
tricular failure. Heart Fail Rev. 2016;21(3):323-346.
https://doi.org/10.1007/s10741-015-9514-7
Dardi F, Boucly A, Benza R, et al. Risk stratifi-
cation and treatment goals in pulmonary arterial
hypertension. Eur Respir J. 2024;64(4):2401323. https://
doi.org/10.1183/13993003.01323-2024
Dunkley KA, Louzon PR, Lee J, Vu S. Efficacy,
safety, and medication errors associated with the use of
inhaled epoprostenol for adults with acute respiratory
2013;47(6):790-796. https://doi.org/10.1345/aph.1r540
Galiè N, Barberà JA, Frost AE, et al. Initial use of
ambrisentan plus tadalafil in pulmonary arterial hyper-
tension. N Engl J Med. 2015;373(9):834-844. https://doi.
org/10.1056/nejmoa1413687
GrΓΌnig E, Jansa P, Fan F, et al. Randomized trial of
macitentan/tadalafil single-tablet combination ther-
apy for pulmonary arterial hypertension. J Am Coll
Cardiol. 2024;83(4):473-484. https://doi.org/10.1016/j.
jacc.2023.10.045
Hoeper MM, Al-Hiti H, Benza RL, et al. Switching
to riociguat versus maintenance therapy with phos-
phodiesterase-5 inhibitors in patients with pulmonary
arterial hypertension (REPLACE): a multicentre,
Med.
2021;9(6):573-584.
https://doi.org/10.1016/
s2213-2600(20)30532-4
Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3
trial of sotatercept for treatment of pulmonary arterial
hypertension. N Engl J Med. 2023;388(16):1478-1490.
https://doi.org/10.1056/nejmoa2213558